These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 34632575)
21. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature. Jarius S; Bieber N; Haas J; Wildemann B J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110 [TBL] [Abstract][Full Text] [Related]
22. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine. Baldolli A; Fournier A; Verdon R; Michon J Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759 [TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033 [TBL] [Abstract][Full Text] [Related]
24. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Stampfer SD; Goldwater MS; Jew S; Bujarski S; Regidor B; Daniely D; Chen H; Xu N; Li M; Green T; Fung E; Aquino E; Swift R; Eshaghian S; Preugschat K; Feinstein AJ; Spektor TM; Berenson JR Leukemia; 2021 Dec; 35(12):3534-3541. PubMed ID: 34326466 [TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 Antibody Response After ChAdOx1 nCoV-19 Vaccination in Persons With Previous SARS-CoV-1 Infection. Chen YC; Lu SN; You HL; Wang CC; Lee IK JAMA Intern Med; 2022 Mar; 182(3):347-349. PubMed ID: 35072699 [TBL] [Abstract][Full Text] [Related]
30. Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study. Paschou SA; Karalis V; Psaltopoulou T; Vasileiou V; Charitaki I; Bagratuni T; Ktena V; Papandroulaki F; Gumeni S; Kassi GN; Trougakos IP; Terpos E; Dimopoulos MA Front Endocrinol (Lausanne); 2022; 13():840668. PubMed ID: 35273575 [TBL] [Abstract][Full Text] [Related]
32. Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2. Kayukawa S; Nanya K; Morita M; Ina K; Ota Y; Hasegawa S Microbiol Spectr; 2021 Dec; 9(3):e0103621. PubMed ID: 34756062 [No Abstract] [Full Text] [Related]
33. Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. Bikdeli B; Jiménez D; Demelo-Rodriguez P; Galeano-Valle F; Porras JA; Barba R; Ay C; Malý R; Braester A; Imbalzano E; Rosa V; Lecumberri R; Siniscalchi C; Fidalgo Á; Ortiz S; Monreal M; For The Riete Investigators Viruses; 2022 Jan; 14(2):. PubMed ID: 35215771 [TBL] [Abstract][Full Text] [Related]
34. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia. Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883 [TBL] [Abstract][Full Text] [Related]
35. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S Front Immunol; 2021; 12():793191. PubMed ID: 34975897 [TBL] [Abstract][Full Text] [Related]
37. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People. Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G Front Immunol; 2021; 12():778679. PubMed ID: 34868051 [TBL] [Abstract][Full Text] [Related]
38. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
39. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
40. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. Steensels D; Pierlet N; Penders J; Mesotten D; Heylen L JAMA; 2021 Oct; 326(15):1533-1535. PubMed ID: 34459863 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]